A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

PURPOSE: We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. METHODS: Fifty patients with untreated, histologically confirmed PCa by needle biopsy were en...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guochang, Li, Linlin, Zhu, Ming, Zang, Jie, Wang, Jiarou, Wang, Rongxi, Yan, Weigang, Zhu, Lin, Kung, Hank F., Zhu, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213584/
https://www.ncbi.nlm.nih.gov/pubmed/37233785
http://dx.doi.org/10.1007/s00259-023-06283-4
Descripción
Sumario:PURPOSE: We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. METHODS: Fifty patients with untreated, histologically confirmed PCa by needle biopsy were enrolled. Each patient underwent [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT within a week. In addition to visual analysis, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. RESULTS: [(68)Ga]Ga-P16-093 PET/CT detected more positive tumors than [(68)Ga]Ga-PSMA-11 PET/CT (202 vs. 190, P = 0.002), both for intraprostatic lesions (48 vs. 41, P = 0.016) and metastatic lesions (154 vs. 149, P = 0.125), especially for intraprostatic lesions in low- and intermediate-risk PCa patients (21/23 vs. 15/23, P = 0.031). Furthermore, [(68)Ga]Ga-P16-093 PET/CT exhibited a significantly higher SUVmax for most matched tumors (13.7 ± 10.2 vs. 11.4 ± 8.3, P < 0.001). For normal organs, [(68)Ga]Ga-P16-093 PET/CT showed significantly lower activity in the kidney (SUVmean: 20.1 ± 6.1 vs. 29.3 ± 9.1, P < 0.001) and urinary bladder (SUVmean: 6.5 ± 7.1 vs. 20.9 ± 17.4, P < 0.001), but displayed a higher uptake in the parotid gland (SUVmean: 8.7 ± 2.6 vs. 7.6 ± 2.1, P < 0.001), liver (SUVmean: 7.0 ± 1.9 vs. 3.7 ± 1.3, P < 0.001), and spleen (SUVmean: 8.2 ± 3.0 vs. 5.2 ± 2.2, P < 0.001) than [(68)Ga]Ga-PSMA-11 PET/CT. CONCLUSION: [(68)Ga]Ga-P16-093 PET/CT demonstrated higher tumor uptake and better tumor detectability than [(68)Ga]Ga-PSMA-11 PET/CT, especially in low- and intermediate-risk PCa patients, which indicated that [(68)Ga]Ga-P16-093 may serve as an alternative agent for detection of PCa. TRIAL REGISTRATION: (68)Ga-P16-093 and (68)Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332, Registered 12 April 2022, retrospectively registered). URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05324332 .

Ejemplares similares